Wang Jin-tao, Ding Ling, Gao Er-sheng, Cheng Yu-ying
Department of Epidemiology, Public Health College, Shanxi Medical University, Taiyuan, China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2007 Oct;28(10):968-71.
To evaluate the roles of expression and early protein E2 and E6 load of human papillomavirus type 16 (HPV16) on cervical cancer in order to explore the relation between disruption of E2 and development of cervical cancer.
A case-control study was conducted, including 141 cervical cancer patients as cases who had been diagnosed by cytological approaches and histological approaches in Shanxi province Tumor Hospital, China. Two type of controls including 137 hospital controls with hysteromyoma by cytology or histology and eligible 129 controls from 1582 healthy women in the community who took part in community-organized physical examination with neither CIN2-3 nor invasive cancer, nor other gynecologic diseases were recruited. HPV16 E2 and E6 oncogenes were detected by multiple polymerase chain reaction (multi-PCR). The levels of E2 and E6 were analyzed used Bio-1D+ + software provided by VILBER pattern formatter.
The positive rates of HPV16 E6 in cancer cases (46.8%) were significantly higher than that in hysteromyoma group (24.1%) or healthy control group (2.3%) and accounted for 2.77 of OR (95% CI: 1.66-4.63) and 36.96 of OR(95% CI: 11.22-121.71) respectively. The expressions and loads of HPV16 E6 and E2 in cases were significantly higher than that in two control groups. Meanwhile, the expression or level of E6 was higher than that of E2 in each group. Disruption rate of E2 was 22.73% and the ratio of E6 to E2 was 1.24 in cervical cancer group.
The positive rates and levels of HPV16 E6 or E2 found in cervical cancer were higher than that in hysteromyoma and healthy women. High expression of E6 and disruption of E2 might play an important role in the development of HPV-induced cervical cancer.
评估16型人乳头瘤病毒（HPV16）的早期蛋白E2和E6表达及负荷在宫颈癌中的作用，以探讨E2破坏与宫颈癌发生发展的关系。
开展一项病例对照研究，其中包括141例宫颈癌患者作为病例组，这些患者在中国山西省肿瘤医院经细胞学和组织学方法确诊。招募了两类对照组，一类是137例经细胞学或组织学诊断为子宫肌瘤的医院对照，另一类是从1582名参与社区组织体检且无CIN2 - 3、无浸润性癌及其他妇科疾病的健康女性中选取的129名合格对照。采用多重聚合酶链反应（multi-PCR）检测HPV16 E2和E6癌基因。使用VILBER图像格式化仪提供的Bio-1D++软件分析E2和E6的水平。
宫颈癌病例组中HPV16 E6的阳性率（46.8%）显著高于子宫肌瘤组（24.1%）或健康对照组（2.3%），OR值分别为2.77（95%CI：1.66 - 4.63）和36.96（95%CI：11.22 - 121.71）。病例组中HPV16 E6和E2的表达及负荷显著高于两个对照组。同时，每组中E6的表达或水平均高于E2。宫颈癌组中E2的破坏率为22.73%，E6与E2的比值为1.24。
宫颈癌中HPV16 E6或E2的阳性率和水平高于子宫肌瘤患者及健康女性。E6的高表达和E2的破坏可能在HPV诱导的宫颈癌发生发展中起重要作用。
